Zacks Research Research Analysts Increase Earnings Estimates for OPKO Health, Inc. (NASDAQ:OPK)

OPKO Health, Inc. (NASDAQ:OPK) – Zacks Research upped their FY2024 EPS estimates for shares of OPKO Health in a research note issued on Monday, April 15th. Zacks Research analyst I. Bandyopadhyay now expects that the biotechnology company will earn ($0.35) per share for the year, up from their prior estimate of ($0.36). The consensus estimate for OPKO Health’s current full-year earnings is ($0.33) per share. Zacks Research also issued estimates for OPKO Health’s Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.21) EPS, Q1 2026 earnings at ($0.05) EPS and FY2026 earnings at ($0.12) EPS.

OPK has been the subject of several other reports. HC Wainwright reiterated a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a research note on Wednesday, April 3rd. StockNews.com cut OPKO Health from a “hold” rating to a “sell” rating in a research note on Friday, March 1st. Piper Sandler reiterated an “overweight” rating and issued a $5.00 price target on shares of OPKO Health in a research note on Monday, April 1st. Finally, Barrington Research reiterated an “outperform” rating and issued a $1.50 price target on shares of OPKO Health in a research note on Monday, April 1st.

OPKO Health Stock Performance

Shares of OPKO Health stock traded up $0.04 on Wednesday, hitting $1.25. The stock had a trading volume of 4,730,266 shares, compared to its average volume of 13,992,871. The company has a quick ratio of 1.22, a current ratio of 1.55 and a debt-to-equity ratio of 0.15. The stock has a market cap of $871.24 million, a price-to-earnings ratio of -5.00 and a beta of 1.82. The business’s 50 day moving average is $1.06 and its two-hundred day moving average is $1.24. OPKO Health has a twelve month low of $0.85 and a twelve month high of $2.24.

OPKO Health (NASDAQ:OPK) last posted its earnings results on Tuesday, February 27th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.09). OPKO Health had a negative net margin of 21.76% and a negative return on equity of 12.69%. The company had revenue of $181.90 million during the quarter, compared to analysts’ expectations of $177.53 million. During the same quarter last year, the company posted ($0.11) EPS. OPKO Health’s quarterly revenue was down 1.9% compared to the same quarter last year.

Insider Activity at OPKO Health

In related news, CEO Phillip Md Et Al Frost acquired 400,000 shares of the company’s stock in a transaction that occurred on Thursday, January 18th. The stock was acquired at an average price of $0.97 per share, with a total value of $388,000.00. Following the purchase, the chief executive officer now directly owns 205,368,225 shares in the company, valued at $199,207,178.25. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other OPKO Health news, Director Richard M. Krasno purchased 30,000 shares of the company’s stock in a transaction dated Monday, January 29th. The stock was purchased at an average price of $0.99 per share, with a total value of $29,700.00. Following the completion of the purchase, the director now owns 103,333 shares of the company’s stock, valued at $102,299.67. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Phillip Md Et Al Frost purchased 400,000 shares of the company’s stock in a transaction dated Thursday, January 18th. The shares were acquired at an average cost of $0.97 per share, with a total value of $388,000.00. Following the purchase, the chief executive officer now directly owns 205,368,225 shares of the company’s stock, valued at approximately $199,207,178.25. The disclosure for this purchase can be found here. Insiders purchased a total of 5,030,000 shares of company stock valued at $4,810,700 in the last quarter. Insiders own 47.26% of the company’s stock.

Institutional Investors Weigh In On OPKO Health

Several large investors have recently modified their holdings of the company. IPG Investment Advisors LLC acquired a new stake in OPKO Health in the fourth quarter worth $30,000. Verition Fund Management LLC acquired a new stake in OPKO Health in the second quarter worth $36,000. River Wealth Advisors LLC acquired a new stake in OPKO Health in the third quarter worth $38,000. Guggenheim Capital LLC acquired a new stake in OPKO Health in the first quarter worth $38,000. Finally, Point72 Hong Kong Ltd acquired a new stake in OPKO Health in the first quarter worth $39,000. 64.63% of the stock is currently owned by institutional investors and hedge funds.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.